ANI Transforms With Novitium And Sandoz Deals

Company On Track To File Corticotropin sNDA By End Of Q2

US generics player ANI Pharmaceutical is looking to file a supplemental new drug application of corticotropin gel with the FDA, with the company seeing the Cortrophin product as a “transformational opportunity.” The company also expects to close its acquisition of Novitium in the second half of 2021, anticipating over 25 product launches. 

Money_Expansion
After the Novitium deal, ANI acquired Sandoz product assets to expand its portfolio • Source: Alamy

ANI Pharmaceuticals, Inc. says the re-filing of a supplemental new drug application for its lead product, Cortrophin (corticotropin) gel, with the US Food and Drug Administration in the second quarter of 2021 is on track. Calling it a “transformational opportunity” for the company, president and CEO Nikhil Lalwani said the launch had the potential to dramatically changing the size and scale of ANI. He pointed out that Cortrophin’s only competitor in the same class achieved $770m in revenues in 2020.

“We are eager to bring this much-needed product to patients in need,” said Lalwani. “Our dedicated Cortrophin technical team is...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin